Ask sales for the Certificate of Analysis matched to the offered or supplied lot; it records the tests actually completed, applicable specifications, and reported results.

Matching batch COA available.

FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →

FDA PCAC: 7 peptides under review. Read →

B7-33

Name: B7-33
Brand: Vialdyne
SKU: b7-33

Single-chain relaxin-2 mimetic · biased RXFP1 agonist

Available by request≥ 99.0%Repair Peptides

Overview

Single-chain relaxin-2 mimetic · biased RXFP1 agonist Vialdyne releases B7-33 as a lyophilized heptacosapeptide (linear, disulfide-free) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.

Applications & buyer fit

Repair peptides, BPC-157, TB-500, and related sequences, typically ship to research labs studying tissue-repair, gastrointestinal, or tendon-ligament models, and to compounding pharmacies that have validated the active material into their workflow. Buyers should request the batch COA for the lot offered or shipped and define any sequence-level evidence required by their written qualification procedure before quotation; Vialdyne does not require buyers to repeat the lot-release tests recorded on the COA.

How B7-33 is sourced

Sourced for

Research into tissue-repair, gastrointestinal, and tendon-ligament models
Compounding-pharmacy workflows where the active has been validated in

Buyer fit

academic and contract research laboratories

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Sequence verification (LC-MS/MS)
Water content (Karl Fischer)
Counter-ion analysis
SDS / MSDS
Stability data on request

Procurement note: Start with the applicable batch COA. Add tandem-MS sequence evidence only when the buyer's written procurement procedure requires it and the scope is agreed before quotation.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS: (research compound · identity on COA)
Molecular Formula: C131H229N41O36S
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: On request
Packaging: 10 vials/box · base pack (multiples of 10)
MOQ: On request
Lead time: 14–21 days
Storage: -20°C, protect from light

Certificate of Analysis

Representative COA previews for B7-33; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

B7-33

VD260428-ACI026 · 98.85%

VerifiedRequest full COA →

B7-33

VD260428-ACI025 · 98.96%

Browse all published COAs

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Frequently asked questions

Why does the absence of disulfide bonds in B7-33 simplify its impurity profile and acceptance testing versus native relaxin?▾

Native relaxin-2 is a two-chain molecule held together by interchain and intrachain disulfide bonds, and making it requires oxidative folding that yields a background of scrambled disulfide isomers, forcing acceptance criteria to police correct folding. As a single 27-residue chain carrying no disulfide bonds at all, B7-33 avoids that entire class of misfolded-isomer impurities and its qualification reduces to standard linear-peptide checks: identity by mass spectrometry, purity by RP-HPLC to an area-percent limit, and a synthesis-related related-substances profile. This makes the acceptance file simpler and the batch-to-batch consistency easier to demonstrate for a qualifying buyer.

What identity and content specifications should appear on a B7-33 certificate for a compounding-oriented buyer?▾

The certificate should confirm identity by mass spectrometry against the theoretical mass of the 27-residue linear peptide and report purity by RP-HPLC against a defined area-percent acceptance limit, with the impurity profile reflecting synthesis-derived species. Net peptide content, counterion identity, water content, and residual solvents belong on the release file so that potency calculations rest on assayed material rather than nominal vial mass, and endotoxin and microbial limits round out a compounding-oriented packet. Because the molecule is valued for its biased RXFP1 agonism, accurate identity confirmation is the load-bearing acceptance parameter rather than a formality.

Related peptides

Buyers who view B7-33 also ask about:

15-mer

BPC-157

≥99.0%

Body Protection Compound 15-mer

CAS: 137525-51-0
Vial: 2 mg–20 mg

MOQ on requestGet quote →

43-mer

TB-500

≥99.0%

Thymosin β4 fragment

CAS: 77591-33-4
Vial: 2 mg–10 mg

MOQ on requestGet quote →

See full catalog

B7-33

Single-chain relaxin-2 mimetic · biased RXFP1 agonist

Available by request≥ 99.0%Repair Peptides

Overview

Applications & buyer fit

How B7-33 is sourced

Sourced for

Research into tissue-repair, gastrointestinal, and tendon-ligament models
Compounding-pharmacy workflows where the active has been validated in

Buyer fit

academic and contract research laboratories

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Sequence verification (LC-MS/MS)
Water content (Karl Fischer)
Counter-ion analysis
SDS / MSDS
Stability data on request

Procurement note: Start with the applicable batch COA. Add tandem-MS sequence evidence only when the buyer's written procurement procedure requires it and the scope is agreed before quotation.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS: (research compound · identity on COA)
Molecular Formula: C131H229N41O36S
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: On request
Packaging: 10 vials/box · base pack (multiples of 10)
MOQ: On request
Lead time: 14–21 days
Storage: -20°C, protect from light

Certificate of Analysis

Representative COA previews for B7-33; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

B7-33

VD260428-ACI026 · 98.85%

VerifiedRequest full COA →

B7-33

VD260428-ACI025 · 98.96%

Browse all published COAs

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Frequently asked questions

Why does the absence of disulfide bonds in B7-33 simplify its impurity profile and acceptance testing versus native relaxin?▾

What identity and content specifications should appear on a B7-33 certificate for a compounding-oriented buyer?▾

Related peptides

Buyers who view B7-33 also ask about:

15-mer

BPC-157

≥99.0%

Body Protection Compound 15-mer

CAS: 137525-51-0
Vial: 2 mg–20 mg

MOQ on requestGet quote →

43-mer

TB-500

≥99.0%

Thymosin β4 fragment

CAS: 77591-33-4
Vial: 2 mg–10 mg

MOQ on requestGet quote →

See full catalog